Form 4: USANA Director Ding Xia Reports Stock Transactions

USANA Health Sciences Director Xia Ding reported the vesting of restricted stock units and subsequent sale of shares for tax purposes on January 22, 2026.

Summary

• Director Xia Ding of USANA Health Sciences, Inc. reported transactions involving common stock and restricted stock units.
• On January 22, 2026, 1,058 restricted stock units (RSUs) vested and converted into common stock.
• Following the vesting, 392 shares of common stock were disposed of at a price of $22.51 per share, likely to cover tax obligations associated with the RSU vesting.
• After these transactions, Director Ding Xia beneficially owns 6,584 shares of common stock directly.
• Director Ding Xia also beneficially owns 1,057 restricted stock units directly, which are subject to future vesting.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The vesting of RSUs is a positive for the director, indicating continued compensation and alignment. The sale for tax purposes is routine and not indicative of negative sentiment towards the company.

Positives

• The vesting of 1,058 restricted stock units demonstrates the director's continued participation in the company's equity compensation plan.
• Director Ding Xia retains a substantial direct beneficial ownership of 6,584 common shares and 1,057 restricted stock units, aligning their interests with long-term shareholder value.

Negatives

• The disposition of 392 common shares, although a common practice for tax withholding upon RSU vesting, results in a reduction of the director's direct common stock holdings.

Future Outlook

The vesting schedule indicates future equity compensation events for Director Ding Xia, with the final 25% of the reported restricted stock units vesting on April 23, 2026.

Industry Context

This is a routine insider transaction filing, common across all industries, reflecting a director's equity compensation vesting and subsequent tax-related share disposition. It does not provide specific insights into USANA's operational performance or broader industry trends.

Comparison to Industry Standards

• The vesting and tax-related sale of shares is a standard practice for executive and director compensation across publicly traded companies.
• The specific terms of the RSU grant (e.g., vesting schedule) are typical for long-term incentive plans designed to align insider interests with shareholder value over time.
• No specific comparable companies or projects are mentioned in this transaction report.

Stakeholder Impact

• Shareholders: The director's continued equity ownership aligns their interests with shareholders. The sale for tax purposes is a minor, routine event and does not significantly impact shareholder value.

Next Steps

• The remaining 1,057 restricted stock units will continue to vest according to their schedule, with the next 25% vesting on April 23, 2026.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations. Such transactions are common for directors and executives and do not typically signal a change in the company's fundamental outlook or the director's confidence. The director retains a substantial equity stake, maintaining alignment with shareholder interests. Therefore, this filing alone does not warrant a change in investment recommendation; a 'hold' stance is appropriate, pending further operational or strategic updates from USANA Health Sciences.

Keywords

USANA Health Sciences, USNA, Form 4, Insider Trading, Stock Transaction, Restricted Stock Units, Director, Equity Compensation